Literature DB >> 14704792

Priming of naive T cells inside tumors leads to eradication of established tumors.

Ping Yu1, Youjin Lee, Wenhua Liu, Robert K Chin, Jing Wang, Yang Wang, Andrea Schietinger, Mary Philip, Hans Schreiber, Yang-Xin Fu.   

Abstract

The tumor barrier comprised of nonantigenic stromal cells may contribute to the failure of tumor rejection. The tumor-necrosis factor superfamily member LIGHT (also known as TNFSF-14) is a ligand of stromal cell-expressed lymphotoxin-beta receptor and T cell-expressed herpes viral entry mediator (HVEM). Here we show that forced expression of LIGHT in the tumor environment induces a massive infiltration of naive T lymphocytes that correlates with an upregulation of both chemokine production and expression of adhesion molecules. Activation of these infiltrating T cells, possibly through HVEM, leads to the rejection of established, highly progressive tumors at local and distal sites. Our study indicates that targeting the tumor barrier may be an effective strategy for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14704792     DOI: 10.1038/ni1029

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  133 in total

1.  Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.

Authors:  Lisa Yan; Diane M Da Silva; Bhavna Verma; Andrew Gray; Heike E Brand; Joseph G Skeate; Tania B Porras; Shreya Kanodia; W Martin Kast
Journal:  Prostate       Date:  2014-11-14       Impact factor: 4.104

2.  Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Authors:  Saravana K Kanagavelu; Victoria Snarsky; James M Termini; Sachin Gupta; Suzanne Barzee; Jacqueline A Wright; Wasif N Khan; Richard S Kornbluth; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

Review 3.  Shedding light on immunotherapy for cancer.

Authors:  Steven A Rosenberg
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

Review 4.  The role of LIGHT in T cell-mediated immunity.

Authors:  Jing Wang; Yang-Xin Fu
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

5.  New immune therapy targets tumor-associated environment: from bone marrow to tumor site.

Authors:  Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2011-12-12       Impact factor: 11.530

6.  Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81.

Authors:  Yael Sagi; Angela Landrigan; Ronald Levy; Shoshana Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

7.  Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.

Authors:  Jian Yan; Panyupa Pankhong; Thomas H Shin; Nyamekye Obeng-Adjei; Matthew P Morrow; Jewell N Walters; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Cancer Immunol Res       Date:  2013-07-17       Impact factor: 11.151

8.  Novel APC-like properties of human NK cells directly regulate T cell activation.

Authors:  Jacob Hanna; Tsufit Gonen-Gross; Jonathan Fitchett; Tony Rowe; Mark Daniels; Tal I Arnon; Roi Gazit; Aviva Joseph; Karoline W Schjetne; Alexander Steinle; Angel Porgador; Dror Mevorach; Debra Goldman-Wohl; Simcha Yagel; Michael J LaBarre; Jane H Buckner; Ofer Mandelboim
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 9.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

10.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.

Authors:  Helena Harlin; Yuru Meng; Amy C Peterson; Yuanyuan Zha; Maria Tretiakova; Craig Slingluff; Mark McKee; Thomas F Gajewski
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.